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ABSTRACT
During the period 1993-2003, generalized demodicosis was diagnosed in 517 dogs. Two hundred and 
sixty-five (51.2%) dogs were cured with amitraz 0.025% solution, 199 (38.5%) were cured after amitraz 0.05% 
solution was introduced, and in 53 dogs (10.3%) mites were amitraz resistant. Among amitraz-resistent dogs, 48 
were introduced to 600 μg kg-1 oral ivermectin protocol, and 45 (89.6%) of this number were successfully cured. 
Outcome data were lacking or were insufficient for 5 (10.4%) dogs. No ivermectin resistance was recorded. 
According to the data of our retrospective therapy evaluation, we anticipate an increase in cases of amitraz-
resistant generalized canine demodicosis. 
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Introduction
Canine demodicosis (demodectic mange, follicular mange, red mange) is a common 
parasitic skin disease resulting from excessive proliferation of the mite Demodex canis 
within the hair follicles (SCOTT et al., 1995).
Two clinical forms of the disease, localized and generalized, have been recognized. 
Localized demodicosis occurs most commonly in young dogs of less than one year of 
age, and spontaneous remission occurs in most patients (MUELLER, 2004). The disease is 
considered to be generalized when a dog has five or more localized lesions, when an entire 
body region (e.g., facial area) is involved, or where the complete involvement of two or 
more feet occurs (SCOTT et al., 1995).
304 Vet. arhiv 75 (4), 303-310, 2005
Demodicosis in dogs is usually treated topically with amitraz, although this therapy 
sometimes fails. Recommended treatment protocols vary from 0.025% amitraz rinses 
used every 2 weeks in the U.S.A. (MULLER, 1983; SCOTT et al., 1995) to 0.05% weekly 
in Germany and Australia (FARMER and SEAWRIGHT, 1980; HAMANN et al., 1997). The 
success rate of amitraz therapy in canine demodicosis varies from 0 to 92% (KWOCHKA et 
al., 1985; SCOTT and WALTON, 1985; MEDLAU and WILLEMSE 1995). Adverse effects with 
amitraz therapy include depression, (KWOCHKA et al., 1985; SCOTT and WALTON, 1985), 
sleepiness (MULLER, 1983), sometimes ataxia and polyphagia/polydipsia (KWOCHKA et 
al., 1985). 
In attempts to develop therapeutic alternatives for dogs with generalized demodicosis 
that do not respond to amitraz, ivermectin appears to have shown the greatest potential in 
terms of efficacy and cost effectiveness. 
Oral ivermectin at a dosage of 350 μg kg-1 daily has cured only 30% of dogs (FONDATI, 
1996). At a daily oral dosage of 600 μg kg-1 ivermectin has been shown to be 100% effective 
in treating dogs with generalized demodicosis (PARADIS and LAPERRIERE, 1992). Adverse 
effects in all of these studies were rare (PARADIS and LAPERRIERE, 1992; RISTIC et al., 
1995), but severe adverse effects of ivermectin were reported in collies (PULLIAM et al., 
1985; PAUL et al., 1987).
However, acute severe toxicity may develop in an individual of any breed (MUELLER, 
2004) and it must be emphasized that the use of ivermectin in dogs is extra-label.
The aim of our study was to evaluate our results in the therapy of generalized 
demodicosis during the past 10 years, and to determine if other protocols should be 
established.
Materials and methods
A retrospective evaluation of the efficiency of therapy in canine generalized demodicosis 
was performed. During the period 1993-2003, generalized demodicosis (Figs. 1, 2 and 3) 
was diagnosed in 517 dogs. Breed, age, sex, and treatment protocols were recorded.
Affected skin was scraped with a dermal curette by a deep-skin scraping in the direction 
of hair growth until capillary bleeding occurred. The skin was firmly squeezed prior to and 
during the scraping to extrude mites from the hair follicles. Laboratory data were based 
on direct microscopy of skin scrapings in glycerine (Fig. 4).
Generalized demodicosis was considered amitraz-resistant when the prescribed topical 
amitraz rinses with 0.025% amitraz every 14 days failed (1 ml of a liquid concentrate 
containing 12.5% amitraz /Tactic®, Hoechst/ in 1⁄2 l of tap water), and afterwards failed to 
cure at 0.05% concentration (2 ml of Tactic® in 1⁄2 l of tap water) once a week. The very 
first evaluation of the therapy was performed 3 weeks after the beginning, and from then 
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on evaluation was repeated fortnightly. Doses and protocols were suited to each individual 
animal according to the level of improvement.
For treatment of amitraz-resistant generalized demodicosis in dogs, oral ivermectin 
(Iverktin ® 1%, Veterina d.o.o.) at a dose of 600 μg kg-1 daily was used. The dose was 
gradually increased from 50 μg kg-1 body weight on day one, 100 μg kg-1 on day two, 150 
μg kg-1 on day three, 200 μg kg-1 on day four, 300 μg kg-1 on day five, to the final dose of 
Fig. 1. “Red mange” in a “dogo argentino” 
puppy. Generalized erythema, folliculitis and 
alopecia.
Fig. 2. Follicular papules, pustules, crusts, 
hyperpigmentation and alopecia over the 
ventral neck and chest of a young Doberman 
with generalized demodicosis
Fig. 4. Large number of adult mites in a skin 
scraping (x 400)
Fig. 3. Pododemodicosis in an adult German 
shepherd. Interdigital and plantar involvement. 
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600 μg kg-1 on day six. This dose was continued daily and the first evaluation of the therapy 
was performed 10 days after the initiation of the final dose, and afterwards fortnightly until 
the resolution of demodicosis.
If the clinical status was found to worsen at a check-up, the next step of switching 
to another therapy option was immediately initiated. Moreover, if the clinical status was 
found unchanged (without worsening, but without any benefit) at two consecutive check-
ups, the next therapy option was initiated.
A remission was declared when patients were clinically normal, and skin scrapings 
from three sites where mites had been previously identified were negative. An animal was 
considered cured if it remained clinically normal for 1 year after the last amitraz rinse or 
administration of ivermectin.
Results
Generalized demodicosis was more frequently diagnosed in purebreds and their crosses 
than in mongrel dogs. The data for these dogs with regard to sex and age are shown in 
Table 1.
Table 1.  Number of dogs with generalized demodicosis under treatment, according to breed, sex 
and age
N = 517
Breed Sex Age (months)
purebred or 

















Male dogs represented 51.4%, bitches 48.6% of the total dogs under treatment.
Within the group aged up to 12 months there were 206 (39.8%) animals. In the group 
aged between 12 and 18 months there were 201 (38.8%) animals. Within the group aged 
between 19 and 24 months there were 96 (18.5%) animals. In the group aged more than 
24 months there were 14 (2.7%) animals.
In Table 2, rows present the total number of animals that had been under therapy 
in each year during the period 1993-2003. In columns, three groups of animals can be 
identified from the results of two treatment protocols. In Group 1 are 265 (51.2%) dogs 
that were cured with 0,025% amitraz rinses. In Group 2 are 199 (38.5%) dogs that failed 
to be cured with 0.025% amitraz, but which were finally cured with 0.05% amitraz. Group 
3. represents 53 amitraz-resistant animals (10.3%).
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Table 2. Groups formed according to results in amitraz-protocols
Year Total
Group 1 Group 2 Group 3
Cured with 
amitraz 0.025%
Cured after amitraz 
0.05% introduction Amitraz resistant
1993 51 38 (74.5%) 11 (21.5%) 2 (3.9%)
1994 58 41 (70.6%) 12 (20.6%) 5 (8.6%)
1995 60 42 (70%) 15 (25%) 3 (5%)
1996 59 38 (64.4%) 16 (27.1%) 5 (8.4%)
1997 58 33 (56.8%) 19 (32.7%) 6 (10.3%)
1998 49 23 (46.9%) 20 (40.8%) 6 (12.2%)
1999 43 16 (37.2%) 22 (51.1%) 5 (11.6%)
2000 37 14 (37.8%) 20 (54%) 3 (8.1%)
2001 35 10 (28.5%) 20 (57.1%) 5 (14.2%)
2002 33 5 (15.1%) 23 (69.6%) 5 (15.1%)
2003 34 5 (14.7%) 21 (61.7%) 8 (23.5%)
517 265 199 53
Table 3. Dogs introduced to ivermectin therapy
Year
A B C D
Oral ivermectin
600  μg kg-1 Cured
Ivermectin 
resistant Lost
1993 1 1 0 0
1994 4 3 0 1
1995 3 3 0 0
1996 4 3 0 1
1997 6 6 0 0
1998 5 4 0 1
1999 5 5 0 0
2000 3 3 0 0
2001 4 4 0 0
2002 5 4 0 1
2003 8 7 0 1
48 43 (89.6%) 0 5 (10.4%)
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 In Table 3, Group A represents 48 amitraz-resistant dogs introduced to the ivermectin 
protocol. In Group B are shown 43 (89.6%) dogs successfully cured with ivermectin. Five 
(10.4%) dogs, represented in Group D, were considered “lost” because the outcome data 
were lacking or insufficient. 
Discussion
Canine demodicosis is a common skin disease of dogs in which proliferation of Demodex 
canis, an acarine parasite of canine hair follicles, is associated with the development of 
cutaneous lesions (SCOTT et al., 1995). The disease is often localized to one or more discrete 
foci that regress spontaneously, or it may progress to widespread generalized cutaneous 
lesions. The initial lesions include alopecia and scale formation, but secondary bacterial 
infection often induces pustular and crusting dermatitis. According to SCOTT et al. (1995), 
pododemodicosis is also considered generalized demodicosis, regardless of the lack of 
lesions on other parts of the body. 
Although a wide range of products have been used to treat generalized demodicosis, 
in the last two decades topical amitraz and systemic macrocyclic lactone ivermectin have 
been reported several times when evaluating various dosages and protocols (MULLER, 1983; 
HAMANN et al., 1997; MUELLER et al., 1999; FONDATI, 1996; SCOTT and WALTON, 1985; 
PARADIS and LAPERRIERE, 1992; MEDLAU and WILLEMSE 1995; MUELLER, 2004). 
During the early 1990s it was observed at the Department for Parasitology and Parasitic 
Diseases, Faculty of Veterinary Medicine, Zagreb, that therapeutic protocol with 0.025% 
amitraz fortnightly rinses for canine generalized demodicosis had sometimes failed, 
regardless of the duration of the therapy. In 1992, weekly rinses with 0.05% amitraz were 
introduced, with some apparently resistant cases being cured. However, there was no 
improvement in several patients and in 1993 we decided to suggest oral ivermectin use at 
a daily dose of 600 μg kg-1. Furthermore, in each successive year we noticed an increasing 
number of cases resistant to 0.025% amitraz, while the number of amitraz-resistant-at-all 
generalized demodicosis continued to increase (Table 2). Daily therapy with 600 μg kg-1 
ivermectin orally was proposed to all owners whose dogs were presumed to be amitraz-
resistant (Table 3). Some refused the extra-label therapy, and others never brought the 
animal in for a check-up during therapy. Such animals were considered “lost”, although 
it is quite possible that some animals were cured, and the therapy was discontinued at 
the owner’s decision. All dogs whose owners continued with the routine checkups were 
eventually cured, and no ivermectin resistance was recorded (Table 3). Moreover, no 
ivermectin toxicity was observed (except slight mydriasis and drooling in two dogs, a 
Doberman and a mongrel, respectively). Collies and their crosses were not challenged. 
Pruritus was very often recorded during the first few weeks, which is also the case after 
amitraz rinses, and occurs regularly in animals responding well to therapy. A relatively 
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frequently recorded amitraz adverse effect was transient sedation after rinses in miniature 
breed puppies. A Husky bitch developed head and neck oedema, and she was immediately 
switched to the ivermectin protocol. 
It should also be emphasized that during the last few years we have resolved only a 
few cases of generalized demodicosis with 0.025% amitraz fortnightly rinses (Table 2); we 
propose abandoning this protocol in therapy. Exceptionally, this concentration might be in 
use weekly in very young or miniature dog breeds. Weekly 0.05% amitraz rinses should 
be introduced at the commencement of therapy, while in the case of an amitraz-resistant 
demodicosis, ivermectin protocol should be proposed to the owner. 
According to the data from our retrospective therapy evaluation, we anticipate an 
increase in amitraz-resistant generalized demodicosis cases. 
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SAŽETAK
U razdoblju od 1993. do 2003. generalizirana demodikoza bila je dijagnosticirana u 517 pasa. Izliječeno 
je bilo 265 pasa (51,2%) 0,025 postotnom otopinom amitraza, 199 (38,5%) 0,05 postotnom otopinom amitraza, 
a u 53 psa (10,3%) uzročnik je bio otporan na amitraz. Od 48 pasa u kojih je uzročnik bio otporan na amitraz, 
45 (89,6%) ih je bilo izliječeno ivermektinom u dozi 600 µg kg-1. Za 5 pasa (10,4%) nedostaju podaci. Nije 
zabilježena otpornost uzročnika na ivermektin. S obzirom na navedene podatke i nadalje se očekuje porast 
otpornosti uzročnika na amitraz.
Ključne riječi: pas, demodikoza, amitraz, ivermektin
Received: 27 September 2004
Accepted: 28 June 2005
T. Živičnjak: A retrospective evaluation of efficiency in therapy for generalized canine demodicosis
